FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283261285> ?p ?o ?g. }

• W4283261285 endingPage "392" @default.
• W4283261285 startingPage "384" @default.
• W4283261285 abstract "Hyperuricemia is associated with several disease conditions, such as atherosclerosis, arthritis, kidney stones, and many others. Xanthine oxidase (XO) is an enzyme that catalyzes the conversion of xanthine to uric acid. Hence, XO is a major therapeutic drug target in the treatment of hyperuricemia and associated disorders.The current study aimed to identify XO inhibitors based on quinazoline derivatives, with the potential to be used against gout and other hyperuricemia-associated diseases.In the current study, eighteen quinazoline derivatives 2-19 were synthesized and assessed for their in vitro xanthine Oxidase (XO) inhibitory activity. Furthermore, the most active compounds, 5 and 17, were subjected to kinetics studies, followed by computational docking. Human BJ fibroblast cells were used to measure the cytotoxicity of active compounds.Compounds 4-6, 8, 10, 13, 15-17, and 19 were found active against XO, with an IC50 values between 33.688 to 362.173μM. The obtained results showed that compounds 5 and 17 possess a significant xanthine oxidase inhibitory activity. The kinetics and molecular docking studies suggested that compounds 5 (IC50 = 39.904 ± 0.21 μM) and 17 (IC50 = 33.688 ± 0.30 μM) bind in the allosteric site of XO and exhibit a non-competitive type of inhibition. The molecular docking studies also predicted that the NH group of the pyrimidine ring binds with Ser344 residues of XO. Furthermore, all active compounds were non-cytotoxic on the human BJ fibroblasts cell line.This study identifies a series of quinazoline compounds as xanthine oxidase inhibitors, with the potential to be further investigated." @default.
• W4283261285 created "2022-06-23" @default.
• W4283261285 creator A5031062667 @default.
• W4283261285 creator A5037238549 @default.
• W4283261285 creator A5050202051 @default.
• W4283261285 creator A5055104015 @default.
• W4283261285 creator A5061691452 @default.
• W4283261285 creator A5080099118 @default.
• W4283261285 date "2023-05-01" @default.
• W4283261285 modified "2023-09-29" @default.
• W4283261285 title "In vitro and In silico Xanthine Oxidase Inhibitory Activities of 3-Aryl-2- thioxo-2,3-dihydroquinazolin-4(1H)-one Derivatives" @default.
• W4283261285 cites W1089522899 @default.
• W4283261285 cites W1599893459 @default.
• W4283261285 cites W1809795104 @default.
• W4283261285 cites W1973805841 @default.
• W4283261285 cites W2018008275 @default.
• W4283261285 cites W2035904505 @default.
• W4283261285 cites W2038060152 @default.
• W4283261285 cites W2041361567 @default.
• W4283261285 cites W2043168039 @default.
• W4283261285 cites W2045185413 @default.
• W4283261285 cites W2054168526 @default.
• W4283261285 cites W2088953117 @default.
• W4283261285 cites W2092984011 @default.
• W4283261285 cites W2119515450 @default.
• W4283261285 cites W2145066076 @default.
• W4283261285 cites W2284186025 @default.
• W4283261285 cites W2506795522 @default.
• W4283261285 cites W2516136724 @default.
• W4283261285 cites W2554477349 @default.
• W4283261285 cites W2591851377 @default.
• W4283261285 cites W2604322317 @default.
• W4283261285 cites W2610052301 @default.
• W4283261285 cites W2733347532 @default.
• W4283261285 cites W2766481853 @default.
• W4283261285 cites W2771490808 @default.
• W4283261285 cites W2802937920 @default.
• W4283261285 cites W2805641932 @default.
• W4283261285 cites W2806437299 @default.
• W4283261285 cites W2905713166 @default.
• W4283261285 cites W2936206842 @default.
• W4283261285 cites W2959469008 @default.
• W4283261285 cites W2988361120 @default.
• W4283261285 cites W3038080478 @default.
• W4283261285 cites W3043954734 @default.
• W4283261285 cites W3155468152 @default.
• W4283261285 cites W3167324494 @default.
• W4283261285 cites W4245081843 @default.
• W4283261285 doi "https://doi.org/10.2174/1573406418666220620124034" @default.
• W4283261285 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35726432" @default.
• W4283261285 hasPublicationYear "2023" @default.
• W4283261285 type Work @default.
• W4283261285 citedByCount "0" @default.
• W4283261285 crossrefType "journal-article" @default.
• W4283261285 hasAuthorship W4283261285A5031062667 @default.
• W4283261285 hasAuthorship W4283261285A5037238549 @default.
• W4283261285 hasAuthorship W4283261285A5050202051 @default.
• W4283261285 hasAuthorship W4283261285A5055104015 @default.
• W4283261285 hasAuthorship W4283261285A5061691452 @default.
• W4283261285 hasAuthorship W4283261285A5080099118 @default.
• W4283261285 hasConcept C109316439 @default.
• W4283261285 hasConcept C159110408 @default.
• W4283261285 hasConcept C181199279 @default.
• W4283261285 hasConcept C185592680 @default.
• W4283261285 hasConcept C202751555 @default.
• W4283261285 hasConcept C2777752497 @default.
• W4283261285 hasConcept C2778102346 @default.
• W4283261285 hasConcept C2778866207 @default.
• W4283261285 hasConcept C2779470414 @default.
• W4283261285 hasConcept C2779721657 @default.
• W4283261285 hasConcept C2779881121 @default.
• W4283261285 hasConcept C2780402116 @default.
• W4283261285 hasConcept C2780932893 @default.
• W4283261285 hasConcept C41685203 @default.
• W4283261285 hasConcept C55493867 @default.
• W4283261285 hasConcept C71240020 @default.
• W4283261285 hasConcept C71924100 @default.
• W4283261285 hasConcept C86803240 @default.
• W4283261285 hasConcept C98274493 @default.
• W4283261285 hasConceptScore W4283261285C109316439 @default.
• W4283261285 hasConceptScore W4283261285C159110408 @default.
• W4283261285 hasConceptScore W4283261285C181199279 @default.
• W4283261285 hasConceptScore W4283261285C185592680 @default.
• W4283261285 hasConceptScore W4283261285C202751555 @default.
• W4283261285 hasConceptScore W4283261285C2777752497 @default.
• W4283261285 hasConceptScore W4283261285C2778102346 @default.
• W4283261285 hasConceptScore W4283261285C2778866207 @default.
• W4283261285 hasConceptScore W4283261285C2779470414 @default.
• W4283261285 hasConceptScore W4283261285C2779721657 @default.
• W4283261285 hasConceptScore W4283261285C2779881121 @default.
• W4283261285 hasConceptScore W4283261285C2780402116 @default.
• W4283261285 hasConceptScore W4283261285C2780932893 @default.
• W4283261285 hasConceptScore W4283261285C41685203 @default.
• W4283261285 hasConceptScore W4283261285C55493867 @default.
• W4283261285 hasConceptScore W4283261285C71240020 @default.
• W4283261285 hasConceptScore W4283261285C71924100 @default.
• W4283261285 hasConceptScore W4283261285C86803240 @default.
• W4283261285 hasConceptScore W4283261285C98274493 @default.

• next